Through licensing of EB66®, VIVALIS earns revenue via upfront licensing fees, milestone payments, and royalties on net sales of licensees. Over the years they have struck many partnerships with major industry players — including big names in vaccines and pharma — illustrating broad collaboration and trust. Vivalis review